Bicalutamide treatment for three days caused growth inhibition of ~30%. Cell survival is likely to be affected when AR activity is inhibited in a low nutrient condition. Since mTOR is a key player in sensing and responding to nutrient deprivation, AR-mTOR signaling cross-talk may be particularly important to stress management. E, estrogen; OVX, ovariectomized; T, testosterone; WGA, wheat germ agglutinin; WKY, Wistar Kyoto. (B, C, D, and E) mRNA expression of β-MHC, ANP, MMP-9 and TIMP-1 by real-time RT-PCR. BW, body weight; E, estrogen; HW, heart weight; OVX, ovariectomized; TL, tibial length; T, testosterone; UW, uterine weight; WKY, Wistar Kyoto. MTOR, 4EBP1 and eIF4E expression was augmented by OVX in comparison to sham group (Fig. 3D, E, G and H). This explanation is strengthened by the data showing that bicalutamide treatment for 24 h markedly decreased PSA expression. Bicalutamide treatment, on the other hand, may have a much quicker effect on AR activity. However, the difference in cell response to bicalutamide or glucose deprivation should be taken into account when interpreting the data. The data suggest that inhibition of AR activity may have a protective effect against glucose deprivation. Both glucose deprivation and bicalutamide were able to induce apoptotic cell death, although bicalutamide was less effective (Figure 5B). This time point was chosen because the growth inhibitory effect of glucose deprivation was apparent on day three, while the effect of bicalutamide may already be subsiding after day three. However, a longer exposure to bicalutamide actually restored growth by day five. In addition, follistatin, an inhibitor of myostatin, activates Akt/mTOR/p70S6K1/S6 signaling in muscle growth, which exists independently of myostatin-driven mechanisms (Winbanks et al., 2012), supporting the disconnection between myostatin and mTOR signaling. However, on the other hand, several studies suggested that mTOR signaling and myostatin signaling could separately regulate muscle growth. Hence, the studies suggested that myostatin attenuates protein synthesis in muscle by coordinating the crosstalk between myostatin-mediated and mTOR signaling. The knockdown of rictor itself inhibits muscle cell differentiation, and does not affect myostatin-induced pSmad2 and muscle differentiation. The depletion of raptor increases myostatin-induced Smad2 phosphorylation, followed by further inhibition of myostatin-induced muscle differentiation. Supporting the negative regulation of myostatin in mTORC1 signaling, genetic deletion of myostatin elevates the activities and the expression levels of Akt, p70S6K1, and S6 (Lipina et al., 2010). The deletion of myostatin in mice results in muscle hyperplasia and hypertrophy, and more than doubles skeletal muscle (McPherron et al., 1997). What are the advantages offered by this kind of signaling interaction? An intriguing observation of the present study is that the mTOR → AR signal is sensitive only to testosterone, but not to DHT. Cinar et al. (6), on the other hand, concluded that the up-regulation of AR by rapamycin is at the translational level. Since AR is known to activate multiple kinases through non-genotropic mechanisms (16, 17), inhibiting AR activity may result in increasing TSC2 stability. However, the testosterone sensitivity of Akt/mTOR signaling requires further understanding in order to grasp the significance of varied testosterone levels seen with wasting disease on muscle protein turnover regulation. The outcome is predictable because the low testosterone-acclimated cells are able to up-regulate AR protein and activity, and are therefore better equipped for survival in a stress situation. The data of the scrambled siRNA control cells presented in Figure 2B show that the phosphorylation of p70S6K and S6 was increased by testosterone stimulation (lane 1 vs. lane 3). These results indicated that the mTOR pathway plays a key role in testosterone-induced OVX SHR myocardial hypertrophy. Finally, the relationship between the total elevated levels of these proteins (mTOR, S6K1 and 4E-BP1) induced by testosterone and their phosphorylated form remains unclear and requires further investigation. First, this study effectively identified the mTOR signaling pathway as a potential target of testosterone-induced OVX SHR cardiac hypertrophy, but it did not explore mTOR upstream regulatory molecules. In addition, the evidence that mTOR is a dual regulator of anabolism and catabolism in skeletal muscle mass will be discussed. Mammalian target of rapamycin (mTOR) is an evolutionarily conserved serine/threonine kinase, and is known to play vital roles in protein synthesis. MTOR inhibitor rapamycin abolished the effect of testosterone on OVX SHR blood pressure… Collectively, these data suggest that the mTOR/S6K1/4EBP1 pathway is an important therapeutic target for the prevention of LVH in postmenopausal hypertensive female rats with high testosterone levels. For that, ovariectomized (OVX) spontaneously hypertensive rats (SHR) aged 12 weeks were used to study the effects of testosterone (T 2.85 mg/kg/weekly i.m.) on blood pressure and myocardial tissue.